Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) Return on Sales (2016 - 2023)

Historic Return on Sales for Spyre Therapeutics (SYRE) over the last 9 years, with Q1 2024 value amounting to 529.4%.

  • Spyre Therapeutics' Return on Sales fell 4363600.0% to 529.4% in Q1 2024 from the same period last year, while for Mar 2024 it was 529.4%, marking a year-over-year decrease of 4626100.0%. This contributed to the annual value of 382.38% for FY2023, which is 3463900.0% down from last year.
  • Spyre Therapeutics' Return on Sales amounted to 529.4% in Q1 2024, which was down 4363600.0% from 382.38% recorded in Q4 2023.
  • In the past 5 years, Spyre Therapeutics' Return on Sales ranged from a high of 0.57% in Q2 2021 and a low of 529.4% during Q1 2024
  • Its 4-year average for Return on Sales is 156.5%, with a median of 98.92% in 2022.
  • In the last 5 years, Spyre Therapeutics' Return on Sales tumbled by -351500bps in 2022 and then tumbled by -4363600bps in 2024.
  • Quarter analysis of 4 years shows Spyre Therapeutics' Return on Sales stood at 5.61% in 2021, then crashed by -1897bps to 112.04% in 2022, then plummeted by -241bps to 382.38% in 2023, then tumbled by -38bps to 529.4% in 2024.
  • Its Return on Sales was 529.4% in Q1 2024, compared to 382.38% in Q4 2023 and 279.35% in Q3 2023.